Tag: Alzheimer disease

Eisai Co., Ltd. and Biogen Inc. LEQEMBI® IQLIK™ (lecanemab-irmb) is now available in the U.S. It’s a subcutaneous…

Eisai Co., Ltd. and Biogen Inc. have started a rolling supplemental Biologics License Application (sBLA) with the U.S.…

Eisai Co., Ltd. and Biogen Inc. shared that LEQEMBI (lecanemab), an anti-amyloid beta monoclonal antibody, launched in Austria…

Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a…

Neusignal Therapeutics Inc., a Tohoku University-based company developing treatments for Alzheimer's disease, has raised 1.15 billion yen in…